
via Scripps Research
Two new studies by scientists at Scripps Research are bringing Ebola virus’s weaknesses into the spotlight, showing for the first time exactly how human and mouse antibodies can bind to the virus and stop infection—not only for Ebola virus, but for other closely related pathogens as well.
The research suggests antibodies like these could be key ingredients in versatile lifesaving therapeutics capable of neutralizing all members of the Ebolavirus genus.
“This is like understanding how to kill five or six birds with one stone,” says Erica Ollmann Saphire, PhD, professor at Scripps Research and senior author of the new papers, published recently in mBio and the Journal of Infectious Diseases. “The different viruses in the Ebolavirus genus vary in their structure, but all these different viruses have the same outbreak potential. We need a therapeutic approach that can target them all.”
A major challenge in treating what we call Ebola virus is that it isn’t just one pathogen but five. Members of the genus Ebolavirus include Ebola virus, Sudan virus, Bundibugyo virus, Taï Forest virus and Reston virus. Each of these viruses is up to 50 percent different in amino acid sequence, making it tough to develop broad treatment strategies. For example, the Sudan and Bundibugyo viruses were responsible for 40 percent of Ebola cases before 2013, yet current experimental Ebola therapies can’t neutralize them.
Adding to the threat, all members of the Ebolavirus genus could mutate to escape immune system defenses and fight off drug therapies.
The new research shows that antibodies that bind to a site on the viral “fusion loop” can neutralize all known ebolaviruses. The fusion loop is part of the machinery that the virus uses to fuse with human cells and initiate infection. Targeting this peptide could present an opportunity to develop a universal therapy for infections caused by all five members of the Ebolavirus genus.
For the mBio study, the researchers focused on a human antibody called ADI-15878. This antibody was found in the blood of an Ebola virus survivor and is the only human antibody ever found to neutralize all five members of the Ebolavirus genus.
So how does ADI-15878 do it?
Using a high-resolution structural technique called X-ray crystallography, the scientists modeled the interaction between the antibody and the viral glycoprotein (the protein that enables the virus to infect a cell). Ebola’s glycoprotein is covered with sugars that help to mask the virus from detection by the body’s immune system. The team observed that ADI-15878 binds directly to one of these sugars alongside a paddle-like structure on the fusion loop. Part of the antibody then dips down and binds into a pocket that is normally hidden by another part of the viral glycoprotein.
“It’s really cool to see that this antibody has found a way to bind into a cryptic, conserved pocket despite the proximity of sugars and other pieces of the virus that effectively hide this region from the immune system” says mBio study first author Brandyn West, PhD, a research associate at Scripps Research.
The researchers hypothesize that this action locks two important parts of Ebola’s fusion machinery together, making it impossible for the virus to get into human cells. The fusion loop is a key piece of the Ebola virus entry machinery, so its structure is what scientists refer to as highly conserved—meaning the virus can’t easily mutate the fusion loop to escape immune detection without compromising the ability of the virus to infect cells. If antibodies targeting this structure were included in therapies or elicited through vaccines, these antibodies should provide broad protection.
But was ADI-15878 just a one in a million antibody from a lucky human survivor?
The second paper the lab published this week in the Journal of Infectious Diseases shows that such antibodies are not out of reach. In this work, the scientists showed that a mouse which had been sequentially immunized with Ebola virus and then Sudan virus also had a broadly protective antibody response. The researchers demonstrate that an antibody, termed 6D6, from this mouse binds to the same region as ADI-15878. The immunization study provides more evidence that this part of the fusion loop is a promising target for vaccine design and therapies.

This shows a mouse antibody elicited through sequential immunization with Ebola and Sudan virus-like particles. Both 6D6 and the human 15878 are quaternary in nature, bridging one monomer to another in the trimeric surface glycoprotein.
“Both the human and mouse antibodies were able to neutralize all known types of Ebola,” explains Jacob Milligan, PhD, research associate at Scripps Research and first author of the Journal of Infectious Diseases study.
It could be possible, the researchers say, for therapeutics to include antibodies that work like ADI-15878. Researchers working on Ebola vaccines could also design molecules that look like this region of the fusion loop. These molecules, called immunogens, teach the human immune system which piece of the virus to target.
“We’re hot on the trail of immunogen design strategies to produce more of these neutralizing antibodies,” Ollmann Saphire says.
Learn more:Â Rare antibodies show scientists how to neutralize the many types of Ebola
The Latest on: Immunogens
[google_news title=”” keyword=”immunogens” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Immunogens
- Africa: HIV Vaccine Research Set to Change Focus in Wake of Mosaico Disappointmenton January 30, 2023 at 7:52 am
Mosaico vaccine - the only HIV vaccine candidate in late-stage (Phase 3) clinical trials - were dashed with manufacturer Janssen Pharmaceuticals' recent announcement that the vaccine lacked efficacy ...
- FDA guidance eases blood donation restrictions for gay, bi menon January 27, 2023 at 2:20 pm
The U.S. Food and Drug Administration (FDA) introduced a proposed change to its blood donation guidelines on Friday that would ease restrictions for gay and bisexual men. The FDA notes the proposal, ...
- HIV Vaccine Trial Shows Science is Still Trying to Catch the Viruson January 25, 2023 at 8:57 am
Will there be a vaccine for HIV? The clinical trial of an HIV vaccine being developed was stopped because it was ineffective at preventing HIV infection.
- Major Blow as Experimental HIV Vaccine Fails in Late Clinical Trialon January 24, 2023 at 9:00 am
The decades-long quest to develop a HIV vaccine has been dealt another major blow, with the 'last true candidate in development' failing to prevent infections any better than a placebo in late-stage ...
- Another Significant HIV Vaccine Trial Failson January 19, 2023 at 11:00 pm
In yet another setback for the future of HIV prevention, the only HIV vaccine in a late-stage trial has failed, study leaders announced Wednesday. Launched in 2019 as a partnership between the U.S.
- J&J Stops Work on HIV Vaccine After Failure in Phase 3 Clinical Trialon January 19, 2023 at 4:15 pm
No safety issues were reported with the vaccine regimen. J&J developed the vaccine with different immunogens, which are vaccine components that feature parts of many HIV subtypes. The vaccine ...
- Another major HIV vaccine trial failson January 18, 2023 at 10:09 pm
The leaders of the study discontinued the mammoth research effort after no evidence was found that the vaccine lowered participants' rate of HIV acquisition.
- Large study of J&J’s HIV vaccine stopped after shot found ineffectiveon January 18, 2023 at 8:17 pm
The result from the nearly 4,000-person trial is the latest setback in a long-running effort to develop a safe and effective shot for HIV infections.
- Experimental HIV vaccine regimen safe but ineffectiveon January 18, 2023 at 1:45 pm
The experimental vaccine regimen was developed by Janssen. It was based on "mosaic" immunogens -- vaccine components featuring elements of multiple HIV subtypes -- with the goal of inducing immune ...
via Bing News